Jazz Pharmaceuticals plc
General ticker "JAZZ" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $11.3B (TTM average)
Jazz Pharmaceuticals plc follows the US Stock Market performance with the rate: 54.1%.
Estimated limits based on current volatility of 1.8%: low 207.57$, high 215.23$
Factors to consider:
- Total employees count: 2890 (+3.2%) as of 2025
- US accounted for 89.8% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Regulatory and compliance, Clinical trial success, Product liability claims, Supply chain disruptions, Trade policy changes
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [164.36$, 253.67$]
- 2026-12-31 to 2027-12-31 estimated range: [160.64$, 249.32$]
Financial Metrics affecting the JAZZ estimates:
- Negative: with PPE of 20.8 at the end of fiscal year the price was high
- Positive: 11.37 < Operating cash flow per share per price, % of 13.06
- Positive: -13.52 < Operating profit margin, % of -9.16
- Positive: Inventory ratio change, % of -1.66 <= -1.30
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -18.95 < Investing cash flow per share per price, % of -14.54
Short-term JAZZ quotes
Long-term JAZZ plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $3,834.20MM | $4,068.95MM | $4,267.59MM |
| Operating Expenses | $3,255.62MM | $3,352.32MM | $4,697.83MM |
| Operating Income | $578.58MM | $716.63MM | $-430.24MM |
| Non-Operating Income | $-280.65MM | $-246.28MM | $-197.62MM |
| Interest Expense | $289.44MM | $238.10MM | $195.05MM |
| R&D Expense | $849.66MM | $884.00MM | $782.74MM |
| Income(Loss) | $297.93MM | $470.35MM | $-627.86MM |
| Taxes | $-119.91MM | $-91.43MM | $-272.44MM |
| Other Income(Loss) | $-3.01MM | $-1.66MM | $-0.73MM |
| Net Income(Loss)* | $414.83MM | $560.12MM | $-356.15MM |
| Stockholders Equity | $3,737.00MM | $4,093.76MM | $4,318.58MM |
| Inventory | $597.04MM | $480.44MM | $416.96MM |
| Assets | $11,393.36MM | $12,012.26MM | $11,659.34MM |
| Operating Cash Flow | $1,092.01MM | $1,395.91MM | $1,355.77MM |
| Capital expenditure | $23.96MM | $48.07MM | $209.75MM |
| Investing Cash Flow | $-163.06MM | $-508.19MM | $-1,509.91MM |
| Financing Cash Flow | $-305.25MM | $20.52MM | $-873.38MM |
| Earnings Per Share** | $6.55 | $9.06 | $-5.84 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.